secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001285550-24-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q2 revenue $7.9M (+32% YoY); raises FY2024 guidance to $30-33M
-------------------------------------------------------------------------------

- Record quarterly revenue of $7.9M, up 32% YoY; product revenue more than doubled to $4.9M.
- Gross margin improved to 63% from 53% a year ago; operating cash burn reduced 47% to $2.7M.
- Raised FY2024 revenue guidance to $30-33M from prior; cash position $32.8M after public offering.
- Activated 6 new global centers in Q2 (14 YTD); SmartFrame OR and Prism Laser Therapy launched.
- Seven pharma partners received expedited FDA review; SmartFlow Cannula approved in Taiwan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/0001285550-24-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555024000097/clpt-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001285550-24-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer